Amanta Healthcare IPO Fund Use Checked; SteriPort Project Faces Implementation Delays

A Monitoring Agency report on Amanta Healthcare Ltd confirms its ₹126 crore IPO proceeds have largely been used in line with company objectives.

However, the critical SteriPort manufacturing line project is facing significant delays. Only ₹47.66 crore has been spent on it, compared to a projected ₹90 crore by March 2026.

Monitoring Report Details Fund Use and Project Delays

The company filed its Monitoring Agency Report for the quarter ending March 31, 2026, prepared by CRISIL Ratings Limited. This report shows that the IPO proceeds, totaling ₹126 crore gross and ₹103.15 crore net, were mostly used as planned.

Reasons for the delay include issues with supplier payments and finalizing machinery supplies.

Project Delays Raise Execution Concerns

Delays in key growth projects funded by public money can affect future revenues and profit timelines. This raises questions about the company's efficiency in carrying out projects and can impact investor confidence in management's ability to achieve strategic goals.

Amanta Healthcare's IPO and Project Plans

Amanta Healthcare went public in February 2024, raising ₹126 crore through its IPO. These funds were intended for growth areas like establishing a new sterile injectables manufacturing unit, the SteriPort Project, modernizing existing facilities, and general corporate needs.

Investor Focus Shifts to Project Resolution

Investors will now closely watch the SteriPort project's revised timelines and the reasons for its current delays. The company is under pressure to quickly resolve issues with supplier payments and machinery procurement. Scrutiny will also focus on how the remaining ₹52.47 crore in unutilized IPO funds are spent. Future Monitoring Agency Reports will be important to track progress and adherence to plans.

Execution Risk for SteriPort Project

The main risk is the delay in executing the SteriPort project. This delay could hinder the company's planned expansion of sterile product manufacturing capacity, potentially affecting its market position and revenue growth.

Amanta vs. Industry Peers

Peers like Laurus Labs and Granules India operate in similar pharma sectors but are generally larger and more diversified. Following its IPO, Amanta Healthcare is closely watched for its execution, especially on key projects like the SteriPort facility, which is vital for its sterile product expansion.

Key Financial Figures for IPO Funds

• Gross IPO Proceeds were ₹126 crore.
• Net IPO Proceeds available for use were ₹103.15 crore.
• The SteriPort Project had actual utilization of ₹47.66 crore by March 31, 2026.
• The projected expenditure for the SteriPort Project was ₹90 crore by March 31, 2026.
• Unutilized IPO Proceeds totaled ₹52.47 crore as of March 31, 2026.

Next Steps for Investors

Investors should monitor Amanta Healthcare's progress reports on the SteriPort project and any revised timelines. Management's commentary on resolving supply chain issues and updates in subsequent Monitoring Agency Reports will also be key.